Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: Pathogenic mutations in the granulin gene (GRN) are causative in 5-10% of patients with frontotemporal dementia (FTD), mostly leading to reduced progranulin protein (PGRN) levels. Upcoming therapeutic trials focus on enhancing PGRN levels. Methods: Fluctuations in plasma PGRN (n = 41) and its relationship with cerebrospinal fluid (CSF, n = 32) and specific single nucleotide polymorphisms were investigated in pre- and symptomatic GRN mutation carriers and controls. Results: Plasma PGRN levels were lower in carriers than in controls and showed a mean coefficient of variation of 5.3% in carriers over 1 week. Although plasma PGRN correlated with CSF PGRN in carriers (r = 0.54, p = 0.02), plasma only explained 29% of the variability in CSF PGRN. rs5848, rs646776 and rs1990622 genotypes only partly explained the variability of PGRN levels between subjects. Conclusions: Plasma PGRN is relatively stable over 1 week and therefore seems suitable for treatment monitoring of PGRN-enhancing agents. Since plasma PGRN only moderately correlated with CSF PGRN, CSF sampling will additionally be needed in therapeutic trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low CSF and blood progranulin levels have been found in GRN mutation carriers with an almost 100% diagnostic accuracy.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus
Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N. E., Ahfeldt, T., Sachs, K. V., Li, X., Li, H., Kuperwasser, N., Ruda, V. M., et al. (2010) · Nature · doi:10.1038/nature09266 · Cited by 1,140
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review
Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A. L., Fox, N. C., & van Swieten, J. C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.212225 · Cited by 609
Self-citationSortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin
Hu, F., Padukkavidana, T., Vægter, C. B., Brady, O. A., Zheng, Y., Mackenzie, I. R., Feldman, H. H., Nykjaer, A., & Strittmatter, S. M. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.034 · Cited by 536
Rosso, S. M. (2003) · Brain · doi:10.1093/brain/awg204 · Cited by 507
Self-citationVan Damme, P., Van Hoecke, A., Lambrechts, D., Vanacker, P., Bogaert, E., van Swieten, J., Carmeliet, P., Van Den Bosch, L., & Robberecht, W. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200712039 · Cited by 418
Optimizing Patient Care and Research: The Amsterdam Dementia Cohort
van der Flier, W. M., Pijnenburg, Y. A. L., Prins, N., Lemstra, A. W., Bouwman, F. H., Teunissen, C. E., van Berckel, B. N. M., Stam, C. J., Barkhof, F., Visser, P. J., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132306 · Cited by 398
Self-citationFinch, N., Baker, M., Crook, R., Swanson, K., Kuntz, K., Surtees, R., Bisceglio, G., Rovelet-Lecrux, A., Boeve, B., Petersen, R. C., et al. (2009) · Brain · doi:10.1093/brain/awn352 · Cited by 386
Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration
Ghidoni, R., Benussi, L., Glionna, M., Franzoni, M., & Binetti, G. (2008) · Neurology · doi:10.1212/01.wnl.0000325058.10218.fc · Cited by 299
Rademakers, R., Eriksen, J. L., Baker, M., Robinson, T., Ahmed, Z., Lincoln, S. J., Finch, N., Rutherford, N. J., Crook, R. J., Josephs, K. A., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn257 · Cited by 291
Cited by
An update on genetic frontotemporal dementia
Greaves, C. V., & Rohrer, J. D. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09363-4 · Cited by 500
Imaging and fluid biomarkers in frontotemporal dementia
Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210
Self-citationPlasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321954 · Cited by 182
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Genetics of Frontotemporal Dementia
Olszewska, D. A., Lonergan, R., Fallon, E., & Lynch, T. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0707-9 · Cited by 190
Holler, C. J., Taylor, G., Deng, Q., & Kukar, T. (2017) · eneuro · doi:10.1523/eneuro.0100-17.2017 · Cited by 136
Fluid biomarkers in frontotemporal dementia: past, present and future
Swift, I. J., Sogorb-Esteve, A., Heller, C., Synofzik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323520 · Cited by 122
Suárez‐Calvet, M., Capell, A., Araque Caballero, M. Á., Morenas‐Rodríguez, E., Fellerer, K., Franzmeier, N., Kleinberger, G., Eren, E., Deming, Y., Piccio, L., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809712 · Cited by 109
“…our MSD-based assay (1,007 pg/ml) was similar to that published with other assays (Huchtemann et al, 2015; Zhou et al, 2015a; Berghoff et al, 2016; Meeter et al, 2016; Kimura et al, 2017; Schreiber et al, 2018), albeit lower than those measured by the more widely used commercial assay from…”
Huang, M., Modeste, E., Dammer, E., Merino, P., Taylor, G., Duong, D. M., Deng, Q., Holler, C. J., Gearing, M., Dickson, D., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01037-x · Cited by 103
Demeule, M., Charfi, C., Currie, J.-C., Larocque, A., Zgheib, A., Kozelko, S., Béliveau, R., Marsolais, C., & Annabi, B. (2021) · Cancer Science · doi:10.1111/cas.15086 · Cited by 78
Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia
Benussi, A., Alberici, A., Samra, K., Russell, L. L., Greaves, C. V., Bocchetta, M., Ducharme, S., Finger, E. C., Fumagalli, G., Galimberti, D., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12485 · Cited by 67
Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics
van der Ende, E. L., Meeter, L. H., Stingl, C., van Rooij, J. G. J., Stoop, M. P., Nijholt, D. A. T., Sanchez‐Valle, R., Graff, C., Öijerstedt, L., Grossman, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.745 · Cited by 65
“This may explain why we did not find PGRN, known to be decreased in GRN mutation carriers, or neurofilament light chain (NfL), known to be increased in symptomatic carriers, both of which have average CSF concentrations below 10 ng/ml.(4,41) Furthermore, relevant proteins may bind to the depleted proteins, Figure 2.”
BackgroundSelf-citationClinical and biomarker changes in presymptomatic genetic frontotemporal dementia
Benussi, A., Gazzina, S., Premi, E., Cosseddu, M., Archetti, S., Dell’Era, V., Cantoni, V., Cotelli, M. S., Alberici, A., Micheli, A., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.12.018 · Cited by 62
The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases
Baldacci, F., Mazzucchi, S., Vecchia, A. D., Giampietri, L., Giannini, N., Koronyo‐Hamaoui, M., Ceravolo, R., Siciliano, G., Bonuccelli, U., Elahi, F. M., et al. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1731306 · Cited by 68
Goossens, J., Bjerke, M., Van Mossevelde, S., Van den Bossche, T., Goeman, J., De Vil, B., Sieben, A., Martin, J.-J., Cras, P., De Deyn, P. P., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0364-0 · Cited by 58
del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52
Self-citationSellami, L., Rucheton, B., Benyounes, I., Camuzat, A., Saracino, D., Rinaldi, D., Epelbaum, S., Azuar, C., Lévy, R., Auriacombe, S., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.02.014 · Cited by 50
Tweaking Progranulin Expression: Therapeutic Avenues and Opportunities
Terryn, J., Verfaillie, C. M., & Damme, P. V. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.713031 · Cited by 48
Uncovering the impact of noncoding variants in neurodegenerative brain diseases
Frydas, A., Wauters, E., van der Zee, J., & Broeckhoven, C. V. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.08.010 · Cited by 47
Xu, W., Han, S., Zhang, C. M., Li, J., Wang, Y., Tan, C., Li, H.-Q., Dong, Q., Mei, C., Tan, L., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb3063 · Cited by 42
Progranulin: Functions and neurologic correlations
Townley, R. A., Boeve, B. F., & Benarroch, E. E. (2018) · Neurology · doi:10.1212/wnl.0000000000004840 · Cited by 40
Staffaroni, A. M., Goh, S.-Y. M., Cobigo, Y., Ong, E., Lee, S. E., Casaletto, K. B., Wolf, A., Forsberg, L. K., Ghoshal, N., Graff-Radford, N. R., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22847 · Cited by 41
Frontotemporal Dementia – Current Concepts
Puppala, G. K., Gorthi, S. P., Chandran, V., & Gundabolu, G. (2021) · Neurology India · doi:10.4103/0028-3886.329593 · Cited by 44
Progranulin in neurodegenerative dementia
Wang, X., Zeng, P. H., Fang, Y., Zhang, T., & Tian, Q. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15378 · Cited by 40
Sha, S. J., Miller, Z. A., Min, S., Zhou, Y., Brown, J., Mitic, L. L., Karydas, A., Koestler, M., Tsai, R., Corbetta‐Rastelli, C., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.002 · Cited by 36
“As PGRN levels are stable over both short and long periods (1 week to 2 years) in GRN mutation carriers [8] as well as various disease and control populations [9], PGRN levels alone are suitable endpoints for trials.”
BackgroundModifiers of GRN -Associated Frontotemporal Lobar Degeneration
Wauters, E., Mossevelde, S. V., van der Zee, J., Cruts, M., & Broeckhoven, C. V. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.004 · Cited by 33
Blood biomarkers in frontotemporal dementia: Review and meta-analysis
Ntymenou, S., Tsantzali, I., Kalamatianos, T., Voumvourakis, K. I., Kapaki, E., Tsivgoulis, G., Stranjalis, G., & Paraskevas, G. P. (2021) · Brain Sciences · doi:10.3390/brainsci11020244 · Cited by 31
“Sensitivity analysis revealed that the removal of studies using ELISA provided by R&D systems (Mineapolis USA) [39,44] and BioVendor (BioVendor (Brno, Czech Republic) [42], did not reduce heterogeneity.”
MethodLjubenkov, P. A., Edwards, L., Iaccarino, L., La Joie, R., Rojas, J. C., Koestler, M., Harris, B., Boeve, B. F., Borroni, B., van Swieten, J. C., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25584 · Cited by 30
Self-citationThe blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
Barro, C., & Zetterberg, H. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109281 · Cited by 32
Biomarkers in frontotemporal dementia: Current landscape and future directions
Gifford, A., Praschan, N. C., Newhouse, A. L., & Chemali, Z. N. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100065 · Cited by 33
Duran-Aniotz, C., Orellana, P., Leon Rodriguez, T., Henriquez, F., Cabello, V., Aguirre-Pinto, M. F., Escobedo, T., Takada, L. T., Pina-Escudero, S. D., Lopez, O., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.663407 · Cited by 26
Clinical variability and onset age modifiers in an extended Belgian GRN founder family
Wauters, E., Mossevelde, S. V., Sleegers, K., van der Zee, J., Engelborghs, S., Sieben, A., Vandenberghe, R. R., Philtjens, S., den Broeck, M. V., Peeters, K., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.007 · Cited by 26
Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review
Liampas, I., Kyriakoulopoulou, P., Karakoida, V., Kavvoura, P. A., Sgantzos, M. N., Bogdanos, D. P., Stamati, P., Dardiotis, E., & Siokas, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111838 · Cited by 25
Phillips, B., Western, D., Wang, L., Timsina, J., Sun, Y., Gorijala, P., Yang, C., Do, A., Nykänen, N.-P., Alvarez, I., et al. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00555-4 · Cited by 20
Swift, I. J., Rademakers, R., Finch, N. A., Baker, M. C., Ghidoni, R., Benussi, L., Binetti, G. G., Rossi, G., Synofzik, M., Wilke, C., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01420-z · Cited by 24
Self-citationFrontotemporal dementia. How to deal with its diagnostic complexity?
Antonioni, A., Raho, E. M., Granieri, E., & Koch, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2461758 · Cited by 25
Silva‐Spínola, A., Lima, M., Leitão, M. J., Durães, J., Tábuas‐Pereira, M., Almeida, M. R., Santana, I. J., & Baldeiras, I. (2021) · European Journal of Neurology · doi:10.1111/ene.15058 · Cited by 23
Phase 1 study of latozinemab in progranulin‐associated frontotemporal dementia
Ward, M., Carter, L. P., Huang, J. Y., Maslyar, D. J., Budda, B., Paul, R. H., & Rosenthal, A. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12452 · Cited by 22
Pharmacotherapy for Frontotemporal Dementia
Khoury, R., Liu, Y., Sheheryar, Q., & Grossberg, G. T. (2021) · CNS Drugs · doi:10.1007/s40263-021-00813-0 · Cited by 23
Geraghty, N. J., Satapathy, S., Kelly, M. A., Cheng, F., Lee, A., & Wilson, M. R. (2021) · Protein Science · doi:10.1002/pro.4189 · Cited by 23
Aggarwal, G., Banerjee, S., Jones, S. A., Benchaar, Y., Bélanger, J., Sévigny, M., Smith, D. M., Niehoff, M. L., Pavlack, M., de Vera, I. M. S., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105475 · Cited by 22
Chemparathy, A., Guen, Y. L., Zeng, Y., Gorzynski, J. E., Jensen, T. D., Yang, C., Kasireddy, N. M., Talozzi, L., Belloy, M. E., Stewart, I., et al. (2024) · Neurology Genetics · doi:10.1212/nxg.0000000000200124 · Cited by 20
Sogorb‐Esteve, A., Weiner, S., Simrén, J., Swift, I. J., Bocchetta, M., Todd, E. G., Cash, D. M., Bouzigues, A., Russell, L. L., Foster, P. H., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adm9654 · Cited by 23
Self-citationPhillips, B., Western, D., Wang, L., Timsina, J., Sun, Y., Gorijala, P., Yang, C., Do, A., Nykänen, N.-P., Alvarez, I., et al. (2023) · doi:10.1101/2023.01.05.23284241 · Cited by 20
Prodromal and Early bvFTD: Evaluating Clinical Features and Current Biomarkers
Katisko, K., Cajanus, A., Korhonen, T., Remes, A. M., Haapasalo, A., & Solje, E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00658 · Cited by 22
Frontotemporal dementia as a consequence of GRN mutations: From disease cause to models to therapies
Salzano, S., Bertasini, C., Haghighi, S. T., Lundkvist, J., Wahlberg, L. U., Chiamulera, C., Vattemi, G. N. A., Gardoni, F., & Paolone, G. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107957 · Cited by 16
FTLD Treatment: Current Practice and Future Possibilities
Ljubenkov, P. A., & Boxer, A. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_18 · Cited by 16
An MRM-Based Multiplexed Quantification Assay for Human Adipokines and Apolipoproteins
Krieg, L., Schaffert, A., Kern, M., Landgraf, K., Wabitsch, M., Beck‐Sickinger, A. G., Körner, A., Blüher, M., von Bergen�, M., & Schubert, K. A. (2020) · Molecules · doi:10.3390/molecules25040775 · Cited by 15
Chemical and genetic rescue of in vivo progranulin-deficient lysosomal and autophagic defects.
Doyle, J. J., Maios, C., Vrancx, C., Duhaime, S., Chitramuthu, B. P., Bennett, H. P. J., Bateman, A., & Parker, J. A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022115118 · Cited by 14
Güven, G., Bılgıç, B., Tüfekçıoğlu, Z., Erginel‐Ünaltuna, N., Hanagasi, H. A., Gurvit, H. I., Singleton, A., Hardy, J., Emre, M., Güleç, Ç., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180599 · Cited by 14
Brůžová, M., Rusina, R., Stejskalova, Z., & Matěj, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-90366-5 · Cited by 14
Davis, S. E., Cook, A. K., Hall, J. A., Voskobiynyk, Y., Carullo, N. V. N., Boyle, N. R., Hakim, A. R., Anderson, K. M., Hobdy, K. P., Pugh, D. A., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01571-4 · Cited by 12
Nanobodies for the Early Detection of Ovarian Cancer
Tran, L., Graulus, G., Vincke, C., Smiejkowska, N., Kindt, A., Devoogdt, N., Muyldermans, S., Adriaensens, P., & Guedens, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213687 · Cited by 13
Fluid Biomarkers of Frontotemporal Lobar Degeneration
van der Ende, E. L., & Swieten, J. C. V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_9 · Cited by 12
Hsiao‐Nakamoto, J., Chiu, C., VandeVrede, L. A., Ravi, R., Vandenberg, B., Groot, J. D., Tsogtbaatar, B., Fang, M., Auger, P., Gould, N. S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.09.579529 · Cited by 12
Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases
Kapaki, E. N., Vakrakou, A. G., & Boufidou, F. (2022) · Diagnostics · doi:10.3390/diagnostics13010073 · Cited by 11
Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease
Vieira, S. R. L., & Morris, H. R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.679927 · Cited by 10
Spinning convincing stories for both true and false association signals
Biedrzycki, R. J., Sier, A., Liu, D., Dreikorn, E., & Weeks, D. E. (2019) · Genetic Epidemiology · doi:10.1002/gepi.22189 · Cited by 9
Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias
Meda, F. J., Simrén, J., Borroni, B., Cantoni, V., Archetti, S., Biasiotto, G., Andréasson, U., Blennow, K., Kvartsberg, H., & Zetterberg, H. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0562 · Cited by 9
An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation
Ek, M., Nilvebrant, J., Nygren, P., Ståhl, S., Lindberg, H., & Löfblom, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437886 · Cited by 9
Regulation of extracellular progranulin in medial prefrontal cortex
Kaplelach, A. K., Fox, S. N., Cook, A. K., Hall, J. A., Dannemiller, R., Jaunarajs, K. L. E., & Arrant, A. E. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106326 · Cited by 7
Budda, B., Mitra, A., Park, L., Long, H., Kurnellas, M., Bien‐Ly, N., Estacio, W. F., Burgess, B., Chao, G., Schwabe, T., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01817-4 · Cited by 8
A Highly Sensitive Sandwich ELISA to Detect CSF Progranulin: A Potential Biomarker for CNS Disorders
Li, Y., Wang, D., Li, Y., Zhu, J., Zhao, J., Deng, Y., Rogalski, E. J., Bigio, E. H., RADEMAKER, A. W., Xia, H., et al. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz022 · Cited by 6
Bagyinszky, E., & An, S. S. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209960 · Cited by 4
Gururaj, S., Sampognaro, P. J., Argouarch, A. R., & Kao, A. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.602235 · Cited by 4
Cosma, C., Talli, I., Pangrazzi, E., Padoan, A., Cerutti, H., Zaninotto, M., Gabelli, C., & Plebani, M. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-1143 · Cited by 3
Clinical Trial Development in Frontotemporal Lobar Degeneration
Ljubenkov, P. A., & Boxer, A. L. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.019 · Cited by 3
Fluid biomarkers in familial frontotemporal dementia: progress and prospects
Guo, M., Qin, L., Cai, H., Wang, R., Luo, C., Yang, F., Feng, S., Gao, H., & Chen, Q. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1663609 · Cited by 4
Les marqueurs biologiques des démences fronto-temporales
Escal, J., & Fourier, A. (2021) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(21)00193-3 · Cited by 3
Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., Grigoriou, S., & Zetterberg, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_11 · Cited by 4
Fourier, A., Formaglio, M., Sauvée, M., Perret‐Liaudet, A., Latour, P., Bost, M., & Quadrio, I. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000492963 · Cited by 2
Progranulin and Frontotemporal Lobar Degeneration
Hosokawa, M., & Arai, T. (2019) · Springer eBooks · doi:10.1007/978-981-13-6186-9_3 · Cited by 2
Delivering Progranulin to Astrocytic Lysosomes Promotes Growth of Co‐Cultured Neurons
Kaplelach, A. K., Hall, J. A., Nader, W. O., Davidson, A. G., Ireland, M. D., Ianov, L., & Arrant, A. E. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70284 · Cited by 1
Genetic evidence supports therapeutic modulation of progranulin levels in Alzheimer’s Disease
Robins, C., Eicher, J. D., Liu, J., Lo, Y., Richardson, T. G., Western, D., Davitte, J., Cruchaga, C., Initiative, A. D. N., Kumar, U., et al. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00011-y · Cited by 2
Delaby, C., & Lehmann, S. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1731 · Cited by 1
Human TDP-43 expression worsens FTD-related phenotypes in progranulin-insufficient mice
Cook, A. K., Lin, B., Song, Y., Greathouse, K. M., Kaplelach, A. K., Love, M. L., Davis, S. E., Stoll, A. C., Hall, J. A., Hakim, A. R., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107475 · Cited by 1
Delaby, C., & Lehmann, S. (2026) · Laboratory Service · doi:10.17116/labs20261502137 · Cited by 1
Fluid and Imaging Markers of Frontotemporal Lobar Degeneration
Prinse, F., Houwer, J. F. H. D., Dopper, E. G. P., & Seelaar, H. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_9 · Cited by 1
Self-citationConfirmation de biomarqueurs pour le pronostic du sepsis et développement de tests rapides
Dubois, C. (2019) · theses.fr (ABES) · doi:10.70675/4101c43dzc2b3z4ae2zb315z16d8d8252081 · Cited by 5
Leskelä, S. (2020) · UEF eRepo (University of Eastern Finland)
Treatment of Frontotemporal Dementias
Chen, D., VandeVrede, L. A., & Boxer, A. L. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108985055.022
Huang, M., Modeste, E. S., Dammer, E., Merino, P., Taylor, G., Duong, D. M., Deng, Q., Holler, C. J., Gearing, M., Dickson, D. W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13064301
Huang, M., Modeste, E. S., Dammer, E., Merino, P., Taylor, G., Duong, D. M., Deng, Q., Holler, C. J., Gearing, M., Dickson, D. W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13064298
Swift, I. J., Rademakers, R., Finch, N. A., Baker, M. C., Ghidoni, R., Benussi, L., Binetti, G. G., Rossi, G., Synofzik, M., Wilke, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26699000
Self-citationNovel digital biomarkers for frontotemporal dementia
Convery, R. S. (2023) · UCL Discovery (University College London)
Improving Wellbeing in At-Risk Frontotemporal Dementia
Greaves, C. V. (2024) · UCL Discovery (University College London)
Differential lysosomal burden in the excitatory and inhibitory neurons of the FTD-GRN brain.
Joyce, J. (2023) · theses.fr (ABES) · doi:10.70675/48f8ae85z4049z4ff7za748z0b87206a8dab
Protective TMEM106B-rs3173615 delays age at onset in GRN mutation carriers
Pagano, L., Saraceno, C., Geviti, A., Fostinelli, S., Facconi, A., Laganà, V., Giacomucci, G., Cotelli, M. S., Ingannato, A., Bagnoli, S., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03653-w
Biparatopic affibody engineering enables high-affinity sortilin blockade and progranulin elevation
Ek, M., Lindberg, H., Ståhl, S., & Löfblom, J. (2026) · New Biotechnology · doi:10.1016/j.nbt.2026.07.002
Multimodal MRI Signatures of 22q11.2 Deletion Syndrome and genetic Frontotemporal Dementia
Pasternak, M. M. (2026) · TSpace (University of Toronto)
Merino, P., Araujo, L. T., Mendsaikhan, A., Taylor, G., Heath, C., Chung, M., McEachin, Z. T., & Kukar, T. L. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00055-8
Metadata
- Authors
- Meeter, L. H. H., Patzke, H., Loewen, G., Dopper, E. G. P., Pijnenburg, Y. A. L., van Minkelen, R., & van Swieten, J. C.
- Affiliations
- Erasmus MC (NL)
- FORUM Pharmaceuticals (United States) (US)
- Amsterdam Neuroscience (NL)
- Venue
- Dementia and Geriatric Cognitive Disorders Extra
- Publisher
- S. Karger AG
- Published
- 2016-07-22
- Volume
- 6
- Issue
- 2
- Pages
- 330-340
- ISSN
- 1664-5464 (ISSN-L)
- PMC
- PMC5040889
- OpenAlex
- W2487820682
- Cited by
- 87
- References
- 32
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 8 · 2022: 4 · 2021: 19 · 2020: 11 · 2019: 9 · 2018: 6 · 2017: 5 · 2016: 1
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders Extra (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- FORUM Pharmaceuticals
- Alzheimer Nederland
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- progranulin, GRN mutations, frontotemporal dementia, mutation carriers, single nucleotide polymorphisms, treatment monitoring, biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.